Choice of aHUS treatments
In making a choice aHUS patients’ preferences among treatments like eculizumab (and its biosimulars) , ravulizumab, crovalimab, and iptacopan it largely…
AIRG Suisse: Their aHUS Survey
Our aHUS Alliance Global Action team takes to heart our mission to “Inform. Connect. Collaborate” on ideas and initiatives across all…
Discontinuing complement inhibitor treatment
It is now just over 3 months since a discontinuing treatment decision making model was proposed to help aHUS patients make…
Why the kidney – blame the complosome?
Intracellular complement, or “complosome,” refers to the complement system’s activity within cells, a discovery that has significantly expanded the understanding of…
aHUS is likely at any time of year
More data about the time of year for aHUS was collected in the recent aHUS Global Poll to add to that…
Out with old in with the new- not quite just yet
On the 10th anniversary of international aHUS awareness day it is timely to raise awareness that the old term aHUS is…
What’s New in aHUS Research: SEPT 2024 Edition
Every year since the first aHUS Awareness Day on 24 Sept 2015 we’ve attempted to shine a spotlight on atypical HUS…
The first ever aHUS research study patient cohort
The Global Action website has been featuring the pioneers and first events of aHUS history in its series Before aHUS Endeavours…
Atypical HUS Facts: 2024 – Sept – 2025
2024 – SEPT – 2025 Atypical HUS: Fact Sheets & Research Atypical Hemolytic Uremic Syndrome – a Rare Disease Information…